SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Pandis N) "

Sökning: WFRF:(Pandis N)

  • Resultat 1-10 av 45
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  • Östling, Jörgen, et al. (författare)
  • IL-17-high asthma with features of a psoriasis immunophenotype
  • 2019
  • Ingår i: Journal of Allergy and Clinical Immunology. - : Elsevier. - 0091-6749 .- 1097-6825. ; 144:5, s. 1198-1213
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The role of IL-17 immunity is well established in patients with inflammatory diseases, such as psoriasis and inflammatory bowel disease, but not in asthmatic patients, in whom further study is required.Objective: We sought to undertake a deep phenotyping study of asthmatic patients with upregulated IL-17 immunity.Methods: Whole-genome transcriptomic analysis was performed by using epithelial brushings, bronchial biopsy specimens (91 asthmatic patients and 46 healthy control subjects), and whole blood samples (n = 498) from the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort. Gene signatures induced in vitro by IL-17 and IL-13 in bronchial epithelial cells were used to identify patients with IL-17–high and IL-13–high asthma phenotypes.Results: Twenty-two of 91 patients were identified with IL-17, and 9 patients were identified with IL-13 gene signatures. The patients with IL-17–high asthma were characterized by risk of frequent exacerbations, airway (sputum and mucosal) neutrophilia, decreased lung microbiota diversity, and urinary biomarker evidence of activation of the thromboxane B2 pathway. In pathway analysis the differentially expressed genes in patients with IL-17-high asthma were shared with those reported as altered in psoriasis lesions and included genes regulating epithelial barrier function and defense mechanisms, such as IL1B, IL6, IL8, and β-defensin.Conclusion: The IL-17–high asthma phenotype, characterized by bronchial epithelial dysfunction and upregulated antimicrobial and inflammatory response, resembles the immunophenotype of psoriasis, including activation of the thromboxane B2 pathway, which should be considered a biomarker for this phenotype in further studies, including clinical trials targeting IL-17.
  •  
4.
  •  
5.
  • Hakansson, Sara, et al. (författare)
  • Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer
  • 1997
  • Ingår i: American Journal of Human Genetics. - 0002-9297. ; 60:5, s. 1068-1078
  • Tidskriftsartikel (refereegranskat)abstract
    • Previous studies of high-risk breast cancer families have proposed that two major breast cancer-susceptibility genes, BRCA1 and BRCA2, may account for at least two-thirds of all hereditary breast cancer. We have screened index cases from 106 Scandinavian (mainly southern Swedish) breast cancer and breast-ovarian cancer families for germ-line mutations in all coding exons of the BRCA1 and BRCA2 genes, using the protein-truncation test, SSCP analysis, or direct sequencing. A total of 24 families exhibited 11 different BRCA1 mutations, whereas 11 different BRCA2 mutations were detected in 12 families, of which 3 contained cases of male breast cancer. One BRCA2 mutation, 4486delG, was found in two families of the present study and, in a separate study, also in breast tumors from three unrelated males with unknown family history, suggesting that at least one BRCA2 founder mutation exists in the Scandinavian population. We report 1 novel BRCA1 mutation, eight additional cases of 4 BRCA1 mutations described elsewhere, and 11 novel BRCA2 mutations (9 frameshift deletions and 2 nonsense mutations), of which all are predicted to cause premature truncation of the translated products. The relatively low frequency of BRCA1 and BRCA2 mutations in the present study could be explained by insufficient screening sensitivity to the location of mutations in uncharacterized regulatory regions, the analysis of phenocopies, or, most likely, within predisposed families, additional uncharacterized BRCA genes.
  •  
6.
  • Megaritis, Athanasios G., et al. (författare)
  • Impact of climate change on mercury concentrations and deposition in the eastern United States
  • 2014
  • Ingår i: Science of the Total Environment. - : Elsevier BV. - 0048-9697 .- 1879-1026. ; 487, s. 299-312
  • Tidskriftsartikel (refereegranskat)abstract
    • The global-regional climate-air pollution modeling system (GRE-CAPS) was applied over the eastern United States to study the impact of climate change on the concentration and deposition of atmospheric mercury. Summer and winter periods (300 days for each) were simulated, and the present-day model predictions (2000s) were compared to the future ones (2050s) assuming constant emissions. Climate change affects He concentrations in both periods. On average, atmospheric Hg2+ levels are predicted to increase in the future by 3% in summer and 5% in winter respectively due to enhanced oxidation of Hg-0 under higher temperatures. The predicted concentration change of Hg2+ was found to vary significantly in space due to regional-scale changes in precipitation, ranging from -30% to 30% during summer and -20% to 40% during winter. Particulate mercury, Hg(p) has a similar spatial response to climate change as Hg2+, while Hg levels are not predicted to change significantly. In both periods, the response of mercury deposition to climate change varies spatially with an average predicted increase of 6% during summer and 4% during winter. During summer, deposition increases are predicted mostly in the western parts of the domain while mercury deposition is predicted to decrease in the Northeast and also in many areas in the Midwest and Southeast. During winter mercury deposition is predicted to change from 30% to 50% mainly due to the changes in rainfall and the corresponding changes in wet deposition.
  •  
7.
  • Murphy, Benjamin N., et al. (författare)
  • A naming convention for atmospheric organic aerosol
  • 2014
  • Ingår i: Atmospheric Chemistry And Physics. - : Copernicus GmbH. - 1680-7316 .- 1680-7324. ; 14:11, s. 5825-5839
  • Tidskriftsartikel (refereegranskat)abstract
    • While the field of atmospheric organic aerosol scientific research has experienced thorough and insightful progress over the last half century, this progress has been accompanied by the evolution of a communicative and detailed yet, at times, complex and inconsistent language. The menagerie of detailed classification that now exists to describe organic compounds in our atmosphere reflects the wealth of observational techniques now at our disposal as well as the rich information provided by state-of-the-science instrumentation. However, the nomenclature in place to communicate these scientific gains is growing disjointed to the point that effective communication within the scientific community and to the public may be sacrificed. We propose standardizing a naming convention for organic aerosol classification that is relevant to laboratory studies, ambient observations, atmospheric models, and various stakeholders for air-quality problems. Because a critical aspect of this effort is to directly translate the essence of complex physico-chemical phenomena to a much broader, policy-oriented audience, we recommend a framework that maximizes comprehension among scientists and non-scientists alike. For example, to classify volatility, it relies on straightforward alphabetic terms (e.g., semivolatile, SV; intermediate volatility, IV; etc.) rather than possibly ambiguous numeric indices. This framework classifies organic material as primary or secondary pollutants and distinguishes among fundamental features important for science and policy questions including emission source, chemical phase, and volatility. Also useful is the addition of an alphabetic suffix identifying the volatility of the organic material or its precursor for when emission occurred. With this framework, we hope to introduce into the community a consistent connection between common notation for the general public and detailed nomenclature for highly specialized discussion. In so doing, we try to maintain consistency with historical, familiar naming schemes, unify much of the scattered nomenclature presented in recent literature, reduce the barrier of comprehension to outside audiences, and construct a scaffold into which insights from future scientific discoveries can be incorporated.
  •  
8.
  • Shaw, DE, et al. (författare)
  • Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
  • 2015
  • Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 46:5, s. 1308-1321
  • Tidskriftsartikel (refereegranskat)abstract
    • U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids.Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of “omic” datasets that are at the core of this systems medicine approach.
  •  
9.
  •  
10.
  • Baranizadeh, Elham, et al. (författare)
  • Implementation of state-of-the-art ternary new-particle formation scheme to the regional chemical transport model PMCAMx-UF in Europe
  • 2016
  • Ingår i: Geoscientific Model Development. - : Copernicus GmbH. - 1991-959X .- 1991-9603. ; 9:8, s. 2741-2754
  • Tidskriftsartikel (refereegranskat)abstract
    • The particle formation scheme within PMCAMx-UF, a three-dimensional chemical transport model, was updated with particle formation rates for the ternary H2SO4-NH3-H2O pathway simulated by the Atmospheric Cluster Dynamics Code (ACDC) using quantum chemical input data. The model was applied over Europe for May 2008, during which the EUCAARI-LONGREX (European Aerosol Cloud Climate and Air Quality Interactions-Long-Range Experiment) campaign was carried out, providing aircraft vertical profiles of aerosol number concentrations. The updated model reproduces the observed number concentrations of particles larger than 4 nm within 1 order of magnitude throughout the atmospheric column. This agreement is encouraging considering the fact that no semi-empirical fitting was needed to obtain realistic particle formation rates. The cloud adjustment scheme for modifying the photolysis rate profiles within PMCAMx-UF was also updated with the TUV (Tropospheric Ultraviolet and Visible) radiative-transfer model. Results show that, although the effect of the new cloud adjustment scheme on total number concentrations is small, enhanced new-particle formation is predicted near cloudy regions. This is due to the enhanced radiation above and in the vicinity of the clouds, which in turn leads to higher production of sulfuric acid. The sensitivity of the results to including emissions from natural sources is also discussed.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 45

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy